{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T17:50:49Z","timestamp":1785520249755,"version":"3.56.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,11,12]],"date-time":"2018-11-12T00:00:00Z","timestamp":1541980800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1007\/s00415-018-9105-3","type":"journal-article","created":{"date-parts":[[2018,11,12]],"date-time":"2018-11-12T06:21:18Z","timestamp":1542003678000},"page":"124-132","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":48,"title":["Admission diagnoses of patients later diagnosed with autoimmune encephalitis"],"prefix":"10.1007","volume":"266","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1033-6945","authenticated-orcid":false,"given":"Annette","family":"Baumgartner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Rauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tilman","family":"Hottenrott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Leypoldt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Friederike","family":"Ufer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harald","family":"Hegen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harald","family":"Pr\u00fcss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Lewerenz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Deisenhammer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Stich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,11,12]]},"reference":[{"issue":"4","key":"9105_CR1","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/S1474-4422(15)00401-9","volume":"15","author":"F Graus","year":"2016","unstructured":"Graus F, Titulaer MJ, Balu R et al (2016) A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurol 15(4):391\u2013404","journal-title":"Lancet Neurol"},{"issue":"1","key":"9105_CR2","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/S1474-4422(10)70253-2","volume":"10","author":"J Dalmau","year":"2011","unstructured":"Dalmau J, Lancaster E, Martinez-Hernandez E, Rosenfeld MR, Balice-Gordon R (2011) Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis. Lancet Neurol 10(1):63\u201374","journal-title":"Lancet Neurol"},{"issue":"23","key":"9105_CR3","doi-asserted-by":"publisher","first-page":"2471","DOI":"10.1212\/WNL.0000000000003414","volume":"87","author":"J Dalmau","year":"2016","unstructured":"Dalmau J. Neurology (2016) NMDA receptor encephalitis and other antibody-mediated disorders of the synapse: the 2016 Cotzias lecture. Neurology 87(23):2471\u20132482","journal-title":"Neurology"},{"issue":"2","key":"9105_CR4","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1212\/WNL.0b013e318224afde","volume":"77","author":"E Lancaster","year":"2011","unstructured":"Lancaster E, Dalmau J (2011) Encephalitis and antibodies to synaptic and neuronal cell surface proteins. Neurology 77(2): 179\u2013189","journal-title":"Neurology"},{"issue":"6","key":"9105_CR5","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1136\/jnnp-2011-301237","volume":"83","author":"L Zuliani","year":"2012","unstructured":"Zuliani L, Graus F, Giometto B, Bien C, Vincent A (2012) Central nervous system neuronal surface antibody associated syndromes: review and guidelines for recognition. J Neurol Neurosurg Psychiatry 83(6):638\u2013645","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"2","key":"9105_CR6","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1212\/WNL.0b013e31825f0522","volume":"79","author":"GK Tofaris","year":"2012","unstructured":"Tofaris GK, Irani SR, Cheeran BJ, Baker IW, Cader ZM, Vincent A (2012) Immunotherapy-responsive chorea as the presenting feature of LGI1-antibody encephalitis. Neurology 79(2):195\u2013196","journal-title":"Neurology"},{"issue":"11","key":"9105_CR7","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1212\/WNL.0b013e3182698cab","volume":"79","author":"CJ Klein","year":"2012","unstructured":"Klein CJ, Lennon VA, Aston PA, McKeon A, Pittock SJ (2012) Chronic pain as a manifestation of potassium channel-complex autoimmunity. Neurology 79(11):1136\u20131144","journal-title":"Neurology"},{"issue":"1","key":"9105_CR8","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/s10072-013-1511-9","volume":"35","author":"Y Tsuyusaki","year":"2014","unstructured":"Tsuyusaki Y, Sakakibara R, Kishi M, Tateno F, Yoshida T (2014) Downbeat nystagmus as the initial manifestation of anti-NMDAR encephalitis. Neurol Sci 35(1):125\u2013126","journal-title":"Neurol Sci"},{"issue":"1\u20132","key":"9105_CR9","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.jneuroim.2012.12.006","volume":"256","author":"S Jarius","year":"2013","unstructured":"Jarius S, Steinmeyer F, Knobel A, Streitberger K, Hotter B, Horn S, Heuer H, Schreiber SJ, Wilhelm T, Trefzer U, Wildemann B, Ruprecht K (2013) GABAB receptor antibodies in paraneoplastic cerebellar ataxia. J Neuroimmunol 256(1\u20132):94\u201396","journal-title":"J Neuroimmunol"},{"key":"9105_CR10","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/S1474-4422(11)70096-5","volume":"10","author":"A Vincent","year":"2011","unstructured":"Vincent A, Bien CG, Irani SR, Waters P (2011) Autoantibodies associated with diseases of the CNS: new developments and future challenges. Lancet Neurol 10:759\u2013772","journal-title":"Lancet Neurol"},{"issue":"12","key":"9105_CR11","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1016\/S1474-4422(08)70224-2","volume":"7","author":"J Dalmau","year":"2008","unstructured":"Dalmau J, Gleichman AJ, Hughes EG, Rossi JE, Peng X, Lai M, Dessain SK, Rosenfeld MR, Balice-Gordon R, Lynch DR (2008) Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies. Lancet Neurol 7(12):1091\u20131098","journal-title":"Lancet Neurol"},{"issue":"4","key":"9105_CR12","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.3892\/etm.2015.2689","volume":"10","author":"KW S\u00fchs","year":"2015","unstructured":"S\u00fchs KW, Wegner F, Skripuletz T, Trebst C, Tayeb SB, Raab P, Stangel M (2015) Heterogeneity of clinical features and corresponding antibodies in seven patients with anti-NMDA receptor encephalitis. Exp Ther Med 10(4):1283\u20131292","journal-title":"Exp Ther Med"},{"issue":"8","key":"9105_CR13","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1111\/dmcn.12411","volume":"56","author":"S Byrne","year":"2014","unstructured":"Byrne S, McCoy B, Lynch B, Webb D, King MD (2014) Does early treatment improve outcomes in N-methyl-d-aspartate receptor encephalitis? Dev Med Child Neurol 56(8):794\u2013796","journal-title":"Dev Med Child Neurol"},{"issue":"6","key":"9105_CR14","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1111\/head.12853","volume":"56","author":"CJ Schankin","year":"2016","unstructured":"Schankin CJ, K\u00e4stele F, Gerdes LA et al (2016) New-onset headache in patients with autoimmune encephalitis is associated with anti-NMDA-receptor antibodies. Headache 56(6):995\u20131003","journal-title":"Headache"},{"issue":"4","key":"9105_CR15","doi-asserted-by":"publisher","first-page":"577","DOI":"10.4103\/0972-2327.120474","volume":"16","author":"AK Pandit","year":"2013","unstructured":"Pandit AK, Ihtisham K, Garg A, Gulati S, Padma MV, Tripathi M (2013 Oct-Dec) Autoimmune encephalitis: a potentially reversible cause of status epilepticus, epilepsy, and cognitive decline. Ann Indian Acad Neurol 16(4):577\u2013584","journal-title":"Ann Indian Acad Neurol"},{"issue":"2","key":"9105_CR16","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/S1474-4422(12)70310-1","volume":"12","author":"MJ Titulaer","year":"2013","unstructured":"Titulaer MJ, McCracken L, Gabilondo I et al (2013) Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. Lancet Neurol 12(2):157\u2013165","journal-title":"Lancet Neurol"},{"issue":"3","key":"9105_CR17","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1002\/ana.24117","volume":"75","author":"MJ Titulaer","year":"2014","unstructured":"Titulaer MJ, H\u00f6ftberger R, Iizuka T et al (2014 Mar) Overlapping demyelinating syndromes and anti\u2013N-methyl-d-aspartate receptor encephalitis. Ann Neurol 75(3):411\u2013428","journal-title":"Ann Neurol"},{"key":"9105_CR18","doi-asserted-by":"publisher","first-page":"25","DOI":"10.3389\/fpsyt.2017.00025","volume":"8","author":"J Herken","year":"2017","unstructured":"Herken J, Pr\u00fcss H (2017) Red flags: clinical signs for identifying autoimmune encephalitis in psychiatric patients. Front Psychiatry 8:25","journal-title":"Front Psychiatry"},{"issue":"5","key":"9105_CR19","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1007\/s11910-013-0348-1","volume":"13","author":"CM Correll","year":"2013","unstructured":"Correll CM (2013) Antibodies in epilepsy. Curr Neurol Neurosci Rep 13(5):348","journal-title":"Curr Neurol Neurosci Rep"},{"issue":"18","key":"9105_CR20","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.1212\/WNL.0000000000002637","volume":"86","author":"A Sonderen Van","year":"2016","unstructured":"Van Sonderen A, Schreurs MW, de Bruijn MA, Boukhrissi S, Nagtzaam MM, Hulsenboom ES, Enting RH, Thijs RD, Wirtz PW, Sillevis Smitt PA, Titulaer MJ (2016) The relevance of VGKC positivity in the absence of LGI1 and Caspr2 antibodies. Neurology 86(18):1692\u20131699","journal-title":"Neurology"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00415-018-9105-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-018-9105-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-018-9105-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,11]],"date-time":"2019-11-11T19:16:10Z","timestamp":1573499770000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00415-018-9105-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,12]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["9105"],"URL":"https:\/\/doi.org\/10.1007\/s00415-018-9105-3","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,12]]},"assertion":[{"value":"24 August 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 October 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"S.R. received consulting and lecture fees, grant and research support from Bayer Vital GmbH, Biogen Idec, Merck Serono, Novartis, Sanofi-Aventis and Teva. He is a founding member of ravo Diagnostika GmbH, Freiburg. F.L. disclosures receiving speakers honoraria from Grifols, Teva, Biogen, Merck, Roche and Fresenius. He is employed by an academic institution offering commercial antibody testing. H.H. has participated in meetings sponsored by received speaker honoraria or travel funding from Bayer, Biogen, Merck, Novartis, Sanofi-Genzyme, Teva, and received honoraria for acting as consultant for Teva. J.L. has received honoraria for speaking and travel grants from Bayer, TEVA, CHDI and the Movement Disorders Society. F.D. has participated in meetings sponsored by or received honoraria for acting as an advisor\/speaker for Biogen Idec, Celgene, Genzyme-Sanofi, Merck, Novartis Pharma, Roche, and TEVA ratiopharm. His institution has received research grants from Biogen and Genzyme Sanofi. He is section editor of the MSARD Journal (Multiple Sclerosis and Related Disorders). A.B., T.H., F.U., H.P. and O.S. report no conflicts of interest with this study. None of the authors has any financial or personal relationships with individuals or organisations that could inappropriately influence this submission.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"The authors confirm that the study is in accordance with ethical standards. The local ethics committee approved the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical standard"}}]}}